Is Hepion Pharmaceuticals Inc (HEPA) Stock About to Get Hot Wednesday?

The market has been high on Hepion Pharmaceuticals Inc (HEPA) stock recently. HEPA gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Hepion Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on HEPA!

See Full HEPA Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With HEPA Stock Today?

Hepion Pharmaceuticals Inc (HEPA) stock is trading at $0.74 as of 2:10 PM on Wednesday, Aug 10, an increase of $0.02, or 2.78% from the previous closing price of $0.72. The stock has traded between $0.70 and $0.76 so far today. Volume today is 135,714 compared to average volume of 177,736. To screen for more stocks like Hepion Pharmaceuticals Inc click here.

More About Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. Click Here to get the full Stock Report for Hepion Pharmaceuticals Inc stock.